Table 1.
Baseline characteristic of included patient demographics (N = 1464)
| Total | CAD-score ≤20 | CAD-score >20 | |
|---|---|---|---|
| Number of patients | 1464 | 723 (49.3%) | 741 (50.7%) |
| Characteristic | |||
| Race, Caucasian | 1454 (99.3%) | 717 (99.2%) | 737 (99.5%) |
| Sex, male | 716 (48.9%) | 257 (35.6%) | 459 (62.9%) |
| Age (years) | 57.1 ± 8.7 | 53.3 ± 8.0 | 60.8 ± 7.8 |
| Body mass index (kg/m²) | 26.6 ± 4.1 | 26.3 ± 4.1 | 27.0 ± 4.1 |
| Abdominal circumference (cm) | 93.0 ± 12.6 | 90.6 ± 12.3 | 95.3 ± 12.5 |
| Blood pressure | |||
| Systolic | 138 ± 19 | 129 ± 14 | 148 ± 18 |
| Diastolic | 83 ± 11 | 79 ± 10 | 86 ± 11 |
| Heart ratea | 65 ± 11 | 65 ± 11 | 66 ± 11 |
| Smoking | |||
| Never | 697 (47.6%) | 343 (47.4%) | 354 (47.8%) |
| Former | 536 (36.6%) | 245 (33.9%) | 291 (39.3%) |
| Active | 231 (15.8%) | 135 (18.7%) | 96 (13.0%) |
| Diabetes | 79 (5.4%) | 24 (3.3%) | 55 (7.4%) |
| Symptoms | |||
| Typical chest pain | 407 (27.8%) | 203 (28.1%) | 204 (27.5%) |
| Atypical chest pain | 493 (33.7%) | 259 (35.8%) | 234 (31.6%) |
| Non-specific | 564 (38.5%) | 261 (36.1%) | 303 (40.9%) |
| Updated Diamond Forrester score | 39% (20–54%) | 28% (16–45%) | 42% (29–59%) |
| Low risk (<15%) | 210 (14.3%) | 168 (23.2%) | 42 (5.7%) |
| Moderate risk (≥15% to 85%) | 1220 (83.3%) | 555 (76.8%) | 665 (89.7%) |
| High risk (≥85%) | 34 (2.3%) | 0 (0.0%) | 34 (4.6%) |
| Medication | |||
| Hypertension | 491 (33.8%) | 86 (12.1%) | 405 (45.9%) |
| Mean number of antihypertensives | 1.9 ± 1.0 | 1.9 ± 0.9 | 1.8 ± 1.0 |
| Hypercholesterolaemia | 398 (27.2%) | 145 (20.0%) | 253 (34.1%) |
| Biochemistryb | |||
| Cholesterol (total, mmol/L) | 5.4 ± 1.1 | 5.4 ± 1.1 | 5.3 ± 1.1 |
| HbA1c (mmol/mol) | 37.7 ± 7.2 | 37.1 ± 7.0 | 38.3 ± 7.2 |
| Creatinine (mmol/L) | 75.4 ± 14.6 | 72.4 ± 12.8 | 78.3 ± 15.6 |
Values are n (%) or mean ±SD or median (IQR).
a
Mean heart rate at the time of CAD-score measurement was: 54 ± 7 b.p.m. and at the time of CTA: 56 ± 7 b.p.m.
b
Data available in: cholesterol 94%, glucose fasting 8%, HbA1c 78%, and creatinine 99% of the cohort.